European Medicine Agency’s (EMA) safety committee continues investigation of AstraZeneca COVID-19 vaccine and thromboembolic events (update)

The EMA’s safety committee (PRAC) has called an extraordinary meeting on Thursday 18 March to conclude on the information gathered and any further actions that may be needed. The EMA currently advises that the benefits of the AstraZeneca vaccine outweigh the risks of side effects

Source:

European Medicines Agency